Analyst firms · Needham · SRPT
Needham SRPT price target and rating history
Sarepta Therapeutics Inc. (SRPT) · Health Care
Needham rates Sarepta Therapeutics Inc. (SRPT) Underperform with a $202 price target, as of its latest action on Jul 21, 2025. It has published 5 rating actions on SRPT since November 2021, including 0 upgrades and 2 downgrades. Across 3 firms with a SRPT price target in the last 12 months, the median target is $27.
- Current rating
- Underperform
- Price target
- $202
- Median target, all firms
- $27
- Actions on SRPT
- 5
Needham price target on SRPT
Every Needham rating on SRPT
- Jul 21, 2025
- Jul 18, 2025DowngradeNeedham downgrades to Hold from Buy
- Nov 27, 2024
- Jan 5, 2022
- Nov 4, 2021
How other firms rate SRPT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Wolfe Research | Outperform | $27 | Jul 9, 2026 |
| Barclays | Equal Weight | $20 | Jan 28, 2026 |
| Wedbush | Outperform | $32 | Dec 9, 2025 |
Questions about Needham and SRPT
- What is Needham's price target for SRPT?
- Needham's latest stated price target for Sarepta Therapeutics Inc. (SRPT) is $202, from its action on Nov 27, 2024.
- What is Needham's rating on SRPT?
- Needham rates SRPT Underperform, a bearish rating, as of Jul 21, 2025.
- When did Needham last change its view on SRPT?
- On Jul 21, 2025, Needham downgrades to Underperform from Hold.
- How does Needham's SRPT target compare with other analysts?
- Across 3 firms with a SRPT price target in the last 12 months, the median target is $27.
More SRPT rating histories
- Barclays4
- BMO Capital Markets3
- Oppenheimer4
- H.C. Wainwright4
- Citigroup4
- Deutsche Bank3
- Morgan Stanley6
- Cantor Fitzgerald4
- RBC Capital Markets5
- Credit Suisse3
All Needham ratingsSRPT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.